{
    "name": "brinzolamide",
    "comment": "Rx",
    "other_names": [
        "Azopt"
    ],
    "classes": [
        "Antiglaucoma",
        "Carbonic Anhydrase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/azopt-brinzolamide-343595",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women to inform drug-associated risk",
            "In reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (RHOD) based on mg/kg; in rabbits, no fetal toxicity was observed following oral administration"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on presence of brinzolamide in human milk, effects on breastfed infant, or on milk production; drug has been detected in the milk of lactating rats",
            "The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for drug and any potential adverse effects on breast-fed child from drug"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium; there is an increased potential for developing corneal edema in patients with low endothelial cell counts; use caution when prescribing this medication to this group of patients",
                "This medication has not been studied in patients with severe renal impairment [creatinine clearance (CrCl) less than 30 mL/min]; because the drug and its metabolite are excreted predominantly by the kidney, this drug is not recommended in such patients",
                "The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents; this medication has not been studied in patients with acute angle-closure glaucoma",
                "Avoid allowing the tip of the dispensing container to contact the eye or surrounding structures or other surfaces, since the product can become contaminated by common bacteria known to cause ocular infections; serious damage to the eye and subsequent loss of vision may result from using contaminated solutions",
                "The preservative in this medication, benzalkonium chloride, may be absorbed by soft contact lenses; contact lenses should be removed during instillation of the medication, but may be reinserted 15 minutes after instillation.",
                " ",
                " "
            ],
            "specific": [
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "This medication is a sulfonamide and although administered topically, it is absorbed systemically; the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration",
                        "Fatalities reported, although rarely, due to severe reactions to sulfonamides, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias",
                        "Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration; if signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation."
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "brinzolamide will decrease the level or effect of amantadine by  Other (see comment). Modify Therapy/Monitor Closely. Excretion rate of amantadine increases rapidly when urine is acidic, administration of urine acidifying drugs may increase elimination of amantadine from the body. Monitor for efficacy of amantadine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "brinzolamide, aspirin.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "brinzolamide, aspirin rectal.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "brinzolamide, aspirin/citric acid/sodium bicarbonate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "balsalazide",
            "description": {
                "common": "brinzolamide, balsalazide.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "brinzolamide, choline magnesium trisalicylate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "brinzolamide, diflunisal.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "brinzolamide will increase the level or effect of lisdexamfetamine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mesalamine",
            "description": {
                "common": "brinzolamide, mesalamine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "brinzolamide, salicylates (non-asa).\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "brinzolamide, salsalate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "brinzolamide, sulfasalazine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate, brinzolamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of kidney stone formation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "willow bark",
            "description": {
                "common": "brinzolamide, willow bark.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "brinzolamide, amobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "brinzolamide, butabarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "brinzolamide, butalbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "brinzolamide, ethotoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "brinzolamide, fosphenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "brinzolamide, pentobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "brinzolamide, phenobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "brinzolamide, phenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "brinzolamide, primidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "brinzolamide, secobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Blurred vision",
            "percent": "1-5"
        },
        {
            "name": "Bitter",
            "percent": "1-5"
        },
        {
            "name": "sour or unusual taste",
            "percent": "1-5"
        },
        {
            "name": "Blepharitis",
            "percent": "1-5"
        },
        {
            "name": "Dermatitis",
            "percent": "1-5"
        },
        {
            "name": "Dry eye",
            "percent": "1-5"
        },
        {
            "name": "Foreign body sensation",
            "percent": "1-5"
        },
        {
            "name": "Headache",
            "percent": "1-5"
        },
        {
            "name": "Hyperemia",
            "percent": "1-5"
        },
        {
            "name": "Ocular discharge",
            "percent": "1-5"
        },
        {
            "name": "Ocular discomfort",
            "percent": "1-5"
        },
        {
            "name": "Ocular keratitis",
            "percent": "1-5"
        },
        {
            "name": "Ocular pain",
            "percent": "1-5"
        },
        {
            "name": "Ocular pruritus",
            "percent": "1-5"
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "Allergic reactions",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Diplopia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Dry mouth",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Eye fatigue",
            "percent": null
        },
        {
            "name": "Hypertonia",
            "percent": null
        },
        {
            "name": "Keratoconjunctivitis",
            "percent": null
        },
        {
            "name": "Keratopathy",
            "percent": null
        },
        {
            "name": "Kidney pain",
            "percent": null
        },
        {
            "name": "Lid margin crusting or sticky sensation",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Pharyngitis",
            "percent": null
        },
        {
            "name": "Tearing",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "Toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Fulminant hepatic necrosis",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Aplastic anemia",
            "percent": null
        },
        {
            "name": "Other blood dyscrasias",
            "percent": null
        }
    ]
}